Ligand PharmaceuticalsLGND
LGND
About: Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Employees: 58
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
535% more call options, than puts
Call options by funds: $5.91M | Put options by funds: $931K
79% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 53
28% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 29
23% more capital invested
Capital invested by funds: $1.48B [Q2] → $1.81B (+$337M) [Q3]
3.32% more ownership
Funds ownership: 97.51% [Q2] → 100.83% (+3.32%) [Q3]
3% more funds holding
Funds holding: 233 [Q2] → 239 (+6) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 4 [Q2] → 2 (-2) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$135
21%
upside
Avg. target
$146
31%
upside
High target
$160
43%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Benchmark Robert Wasserman 61% 1-year accuracy 30 / 49 met price target | 21%upside $135 | Buy Reiterated | 23 Dec 2024 |
Barclays Balaji Prasad 47% 1-year accuracy 21 / 45 met price target | 43%upside $160 | Overweight Maintained | 16 Dec 2024 |
RBC Capital Douglas Miehm 79% 1-year accuracy 15 / 19 met price target | 28%upside $143 | Outperform Maintained | 11 Dec 2024 |
Oppenheimer Leland Gershell 44% 1-year accuracy 24 / 55 met price target | 31%upside $147 | Outperform Maintained | 8 Nov 2024 |
Financial journalist opinion
Positive
Seeking Alpha
1 week ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Neutral
Business Wire
1 month ago
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza, and other members of the senior management team who will provide an in-depth review of the company's growth strategy, portfolio, platform technologies, and long-term financial outlook. “2023 marked the beginning of a new chapter in Ligand's history, and I could not be prouder.
Positive
Seeking Alpha
1 month ago
Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies
I continue to rate Ligand Pharmaceuticals stock as a "Buy" citing strong liquidity and a clean balance sheet. Its Q3 2024 earnings report beat on the top and bottom lines raising prior guidance, reinforcing my confidence in the company's performance. This analysis references Q3 2024 financial results press release, earnings conference call, presentation, 10-Q, and the latest 10-K.
Neutral
Business Wire
2 months ago
Ligand to Present at Stifel 2024 Healthcare Conference
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 12:40 p.m. Eastern Time. Management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their Stifel represe.
Neutral
Seeking Alpha
2 months ago
Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis Todd Davis - Chief Executive Officer Karen Reeves - Senior Vice President of Investments and Head of Clinical Strategy Tavo Espinoza - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Douglas Miehm - RBC Capital Markets Joseph Pantginis - Wainwright Trevor Allred - Oppenheimer John Vandermosten - Zach Small Capital Research Operator Good morning. My name is Aaron, and I will be your conference operator for today.
Neutral
Business Wire
2 months ago
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance.
Neutral
Business Wire
2 months ago
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m. to 12:00 p.m. Eastern Time. The in-person event will include presentations from Ligand's senior management team highlighting the company's strategy, investment activity, royalty portfolio, and long-term financial outlook. A live question and answer session will follow the formal presentation. Inve.
Neutral
Business Wire
2 months ago
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, November 7, 2024 Time: 8:30 a.m. ET (5:30 a.m. PT) Confer.
Neutral
Business Wire
4 months ago
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received full approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. Ligand is entitled to milestone payments and a 9% royalty on worldwide net sales of FILSPARI. FILSPARI was granted accelerated approval in.
Neutral
GlobeNewsWire
4 months ago
CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030
Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Global CD40 Ligand Market by Type (Monoclonal Antibody, Polyclonal Antibody), Application (Autoimmune Disease Treatment, Immunotherapy, Vaccine Development), End-Users - Forecast 2024-2030" report has been added to ResearchAndMarkets.com's offering. The CD40 Ligand Market size was estimated at USD 697.21 million in 2023, USD 734.50 million in 2024, and is expected to grow at a CAGR of 5.47% to reachUSD 1.01 billion by 2030. This makes it intensely relevant in developing treatments for immune disorders, specific cancers, and autoimmune diseases. In therapeutic applications, CD40L-based treatments are crucial for managing conditions such as lymphoma and leukemia, potentially extending to some solid tumors by boosting the immune system's ability to fight cancer cells. Furthermore, CD40L's function in autoimmune disorders suggests its modulation could lessen disease severity in ailments such as systemic lupus erythematosus and rheumatoid arthritis. In vaccine development, enhancing immune responses through CD40L could significantly improve vaccine efficacy against various diseases.
Charts implemented using Lightweight Charts™